Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Clinical applications of a peptide-based vaccine for glioblastoma
Monitoring immune responses after glioma vaccine immunotherapy
Biological rationales and clinical applications of temperature controlled hyperthermia–implications for multimodal cancer treatments
Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies
Heat shock proteins in glioblastomas
Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin
Regional hyperthermia added to intensified preoperative chemo-radiation in locally advanced adenocarcinoma of middle and lower rectum
Tumor antigen presentation by dendritic cells
Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification
Heat shock proteins and immunity: application of hyperthermia for immunomodulation
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma
Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors